Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?


Beiträge: 8
Zugriffe: 171 / Heute: 1
IMMUNE RESP. MIT DER HAMMERNEWS! Heute 7.00 Eastern TIme Drogo


29.03.00 15:17
Wer genau hinschaut, was was Sache ist.....alle die bei 15-18 eingestiegen sind (ich bei 16 und 15,30, heute nochmal zu 14) können aufatmen...puhhh.

Wednesday March 29, 7:00 am Eastern Time
Company Press Release
SOURCE: Immune Response Corporation
The Immune Response Corporation to Pursue Development of a Potential Preventive HIV Vaccine
HIV-1 Immunogen Combined with DNA Sequence Adjuvant Boosts Immunity in Animals
CARLSBAD, Calif., March 29 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today data from preclinical animal studies of a potential new vaccine consisting of the Company's HIV immunogen, Remune(TM) (whole-killed HIV depleted of gp120 coat proteins in Incomplete Freund's Adjuvant) combined with a novel immunostimulatory sequence of DNA. These data were presented on March 27, 2000 at the ``International Workshop on Immunotherapy in HIV Infection'' held in Israel. This potential new preventive HIV vaccine appears to boost key elements of the immune response in animals, including both T-helper and T-killer cell activity that may be involved in protection against HIV infection.

``The Company believes this is the first time that an HIV immunogen (such as an HIV particle that can elicit an immune response) has been combined with a novel adjuvant composed of a DNA sequence that boosts the immune system of animals. Preclinical research indicates that such a vaccine preparation stimulates the types of cellular immune responses (helper and killer T-cell activity) that are believed to be important in protection against HIV infection,'' said Ronald B. Moss, M.D., Vice President of Medical and Scientific Affairs. ``The rationale for our vaccine approach is based on observations from other researchers that 'cell-mediated' immunity is augmented in individuals who are exposed to HIV, but somehow resist infection. It will take significant time and effort to determine how promising the approach will be for humans.''

The activation of both helper and killer T cells is important in combating viral infection because each cell type plays a unique role in the overall immune defense. Specifically, helper T cells are the conductors of the immune response and are necessary for the activation of killer T cells, which are themselves capable of directly killing virus infected cells, Dr. Moss explained.

The apparent ability of this potential preventive vaccine to stimulate helper T cells in animals, also called CD4 cells, was first reported by the Company in the January 6, 2000 issue of the journal Vaccine. In that publication, Company scientists demonstrated in a non-primate animal model that levels of interferon gamma from CD4 cells increased most dramatically after vaccination with the vaccine preparation, which included the novel DNA immunostimulant compared to others without the DNA adjuvant. Interferon gamma is a protein known as a cytokine that modulates important immune system functions such as killer T-cell activity. DNA immunostimulatory sequences have been shown to stimulate important components of the immune system, particularly killer T cells.

The published study further indicated that vaccination with the HIV immunogen/DNA stimulant resulted in increased beta chemokine production from killer T cells, also known as CD8 cells. The level of beta chemokine production was shown to be dependent on the amount of adjuvant mixed into the vaccine. Beta chemokines are 'communications molecules' that exhibit strong HIV-suppressive properties. Dr. Moss also presented new preclinical data at the conference in Israel suggesting the potential vaccine boosts interferon gamma production from CD8 cells.

``One challenge to designing a preventive HIV vaccine is that the immune system of an uninfected person has not been 'primed' against HIV and may therefore require a vaccination capable of eliciting a stronger immune response than for an infected individual who already has a pool of 'memory' immune cells more readily activated against the virus. Our preclinical studies indicate that the addition of a DNA adjuvant to whole-killed HIV in Incomplete Freund's Adjuvant may enhance both CD4 and CD8 T cell immune responses against HIV,'' said Dr. Moss. ``We further believe that our HIV immunogen, because of its previously demonstrated broad immunoreactivity to different strains of HIV, may be the prototype to test as a preventive vaccine in a global population where many subtypes of HIV exist.''

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV and autoimmune diseases. In addition, the Company is working on cancer vaccines and gene therapy.

NOTE: News releases are available through PR Newswire Company News On- Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site:

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether preclinical data can be replicated in clinical trials, whether if initiated clinical trials will be successfully concluded and whether a preventative vaccine will be approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in The Immune Response Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1998 and subsequent Forms 10-Q. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Remune(TM) is a trademark of The Immune Response Corporation.
IMMUNE RESP. MIT DER HAMMERNEWS! Heute 7.00 Eastern TIme Drogo

und der erste US Kurs vor Handel 14,625$ !!! o.T.

29.03.00 15:29
IMMUNE RESP. MIT DER HAMMERNEWS! Heute 7.00 Eastern TIme preisfuchs

leider heute im minus trotz news! o.T.

29.03.00 16:49
IMMUNE RESP. MIT DER HAMMERNEWS! Heute 7.00 Eastern TIme Drogo

Zwar im plus, könnte aber besser sein..+3% schei...NASDAQ o.T.

29.03.00 17:19
IMMUNE RESP. MIT DER HAMMERNEWS! Heute 7.00 Eastern TIme preisfuchs

Drogo bei der nächsten rally sind wir dabei! o.T.

29.03.00 17:21
IMMUNE RESP. MIT DER HAMMERNEWS! Heute 7.00 Eastern TIme Kicky

Obwohl ich diese Aktie empfohlen habe,weise ich darauf hin,dass IMNR.

29.03.00 17:27
Pressemitteilungen herausgibt und ich nicht wirklich Neues entdecken kann.Es wäre dem Wert zu wünschen,dass er nicht hochgepuscht wird,sondern langsam steigt.
IMMUNE RESP. MIT DER HAMMERNEWS! Heute 7.00 Eastern TIme competitor

Hallo Kicky!

29.03.00 23:07
Ich habe schon öfter mit IMNR week getraded, und jetzt neben auch eine Position in mein Long Time Portfolio hineingelegt.

Management, Erfolge sowie technisch schaut es for ein long time investment sehr positiv. aus. Wie sieht du die Kursentwicklung und glaubst du, dass wir die alte Marke von 60 noch dieses Jahr erreichen können. Danke!

IMMUNE RESP. MIT DER HAMMERNEWS! Heute 7.00 Eastern TIme Kicky


60 ist ja wohl masslos übertrieben,25 oder 30 denke ich schon,kommt drauf an ob sie jetzt in Thailand in Produktion gehen und auch mal etwas verdienen,oder ob Remune sogar in USA zugelassen wird.

Börsenforum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen